靖因药业向港交所递交上市申请 加速潜在重磅疗法的全球临床开发

Core Viewpoint - Jingyin Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, aiming to accelerate the global clinical development of its potential blockbuster therapies [1] Group 1: Company Overview - Jingyin Pharmaceuticals is a global clinical-stage biotechnology company focused on maximizing the clinical and commercial value of siRNA therapies [1] - The company is built on three major potential blockbuster product pipelines, a proprietary siRNA technology platform, and a global collaboration network [1] Group 2: Product Pipeline - The company is advancing three major product pipelines targeting coagulation disorders, cardiovascular metabolic diseases, and obesity, which are based on their significant market potential and the ability to provide transformative siRNA solutions [2] - Each of these therapeutic areas is expected to have at least one blockbuster drug with annual global sales exceeding $10 billion by 2024, along with multiple other drugs generating annual sales in the billions [2] - Key pipeline products include: - SRSD107, a potential first-in-class siRNA drug targeting coagulation factor XI, currently undergoing Phase II multi-center clinical trials in Europe, with plans for additional trials in China and Australia/New Zealand [2] - SRSD216, a potential best-in-class siRNA targeting Lp(a), currently in Phase IIa trials in both China and the U.S. [2] - SRSD384, an INHBE-targeting candidate for obesity, which is advancing towards IND submission [2] Group 3: Leadership and Intellectual Property - The company is led by a cross-Pacific team that combines global strategic vision and deep expertise in siRNA technology, capable of advancing drug candidates from discovery to commercialization [3] - Founded in 2021 by OrbiMed Entities and Creacion Ventures, the company has dual headquarters in San Diego and Shanghai, leveraging complementary advantages from both U.S. and Chinese biotech ecosystems [3] - As of the latest feasible date, the company holds or co-holds 65 patents and patent applications, including 14 related to its core products [3] Group 4: Financials and Use of Proceeds - The company has not generated any revenue or sales costs during the reporting period [3] - For the first half of 2024 and the year ending June 30, 2025, the main R&D expenses for SRSD107 were RMB 48.8 million and RMB 19.8 million, accounting for 33.6% and 70.0% of total technical service expenses, respectively [3] - The net proceeds from the financing will be used for: - R&D of core product SRSD107, which is expected to enter Phase III trials by 2026 [4] - R&D of key product SRSD216 [4] - R&D of key product SRSD384, which is rapidly advancing towards IND-supported research and subsequent clinical trials [4] - Development of pipeline projects including extrahepatic projects [4] - Working capital and business development to enhance financial flexibility and maintain daily operations while strategically increasing the global potential of its pipeline [4]